

Douglas Lawrence Feinstein

Citizenship: USA
Date of Birth: May 6, 1956
Voice: 312-996-9562
E-mail: dlfeins@uic.edu
Marital status: Married

FACULTY APPOINTMENTS

07/04-present Research Professor, Dept Anesthesiology, University Illinois, Chicago:
12/02-present Research Biologist, Jesse Brown Veteran's Affairs R&D, Chicago, IL
12/97-07/04 Associate Research Professor, Dept Anesthesiology, University Illinois, Chicago
07/96-12/97 Associate Research Professor, Division of Neurobiology
Cornell University Medical College, New York, NY.
09/90-06/96 Assistant Research Professor, Division of Neurobiology
Cornell Univ. Medical College, New York, NY.

ADJUNCT APPOINTMENTS

07/08-present Associate Professor, Dept of Biopharmaceutical Sciences, UIC
02/05-present Professor, Dept of Bioengineering, UIC.
01/01-present Associate Professor, Dept Cell Biology and Anatomy, UIC.

EDUCATION

1977 – 1984 PhD, Dept of Biology, The Johns Hopkins University, Baltimore, MD
1973 – 1977 B.S., Dept of Biology, Massachusetts Institute of Technology, Cambridge, MA

POST DOCTORAL TRAINING

03/93-09/93 Visiting Scientist, Institut Pasteur, Paris, France
08/91-10/91 Visiting Scientist, Hospital Bichat, INSERM, Paris, France
11/89-09/90 Mettre Professor, Institut de Physiologie, Université de Lausanne, Switzerland
06/89-11/89 Visiting Scientist, Dept of Medical Genetics, Uppsala University, Uppsala, Sweden
1986-1989 Postdoctoral Fellow, Dept Neuropharmacology, Research Institute Scripps Clinic, La Jolla,
1984-1986 Postdoctoral Fellow, Dept Biology, The Johns Hopkins University, Baltimore, MD

FELLOWSHIPS AND HONORS

09/09-09/19 Department of Veteran Affairs, BLR&D Research Career Scientist
3/93-9/93 Visiting Scientist grant, Institut Pasteur, Paris, France
8/91-9/91 Visiting Scientist grant, INSERM, Paris, France
6/89-12/89 Visiting Scientist grant, Swedish National Research Council
1986-1989 Postdoctoral Fellowship, National Multiple Sclerosis Society
1986-1989 Postdoctoral Fellowship, National Institutes of Health

VA LOCAL COMMITTEES AND SERVICE

2015-present Co-mentor to Dr David Gavin, CDA-2
2014-2018 Member, JBVA IACUC
2014-present Adhoc member, JBVA R&D committee
2010-present Adhoc member, JBVA RCS/promotion committee
2007-2010 Chair, JBVA IACUC
2001-2007 Member JBVA R&D; Biosafety; and Animal Care Committees

NIH AND VA NATIONAL SERVICE

2016-present VA NurB committee
2016-present VA RCS / Promotions committee
2011-2012 VA NeurC committee

SERVICE TO LOCAL UNIVERSITY

2010-present Member, Neuroscience Training Program
2012-present Interviewer for UIC Graduate Education in Medical Sciences (GEMS) program
2012-present Reviewer for UIC Clinical and Translational Science Awards (CTSA) program
2006-present Member, Graduate Faculty, UIC

OTHER COMMITTEES AND SERVICE

2017-2019 Scientific Program Committee, International Society Neurochemistry
2015-2018 Treasurer-elect, American Society for Neurochemistry
2015-present Co-organizer 10th, 11th, 12th bi-annual Great Lakes Glial meeting, Traverse City, MI
2012-present Member, Conference Award Committee, International Society Neurochemistry
2011-present Mentor for IMSA (Illinois Math and Science Academy) students
2007-present Member, Scientific Organizing Committee, Venusberg Meeting on Neuroinflammation, Bonn, Germany
2011-2015 Council member, International Society of Neurochemistry
2009-2011 President, American Society Neurochemistry
2008-2012 Co-organizer Chicago Myelin Interest Group
2004 Program Chair, American Society for Neurochemistry 36th Annual meeting

NIH REVIEW PANELS

03/2016 Adhoc NIH SEP
08/2009 Adhoc, ZRG1 BDCN-Y SEP
06/2009 Adhoc, ZRG1 BDCN-T (58) R RFA-OD-09-003 Challenge Grant Panel 11
06/2009 Adhoc, ZRG1 BCMB-A (51) R Transformative R01 RFA #RM08-029
02/03 – 06/07 Member, CNBT1 (Clinical Neuroscience and Brain Tumors)
11/03 Member, MDCN-A

OTHER REVIEW PANELS

2014-present Member, NMSS Fast Forward Translational Research Review Panel
2015-present Member, Cures Within Reach (CWR), Research Grant Review Panel
(a non profit organization dedicated to drug repurposing, Chicago, IL)
2009-present Member, Campus Research Board (CRB), UIC
2008-2013 Member, National Multiple Sclerosis Society Fellowship Advisory Committee
2006-2014 Adhoc, Alpha Omega Alpha Research Fellowship Review panel

SCIENTIFIC ADVISORY BOARDS

2017-present EnSol Therapeutics, LLC (Chicago, IL)
2017-present ResQ Pharmaceuticals, Inc (Chicago, IL)
2017-present Coherus BioSciences (Redwood City, CA)
2017-present Thelial Technologies (Lisbon, Portugal)
2016-present Cures Within Reach (Chicago, IL)

EDITORIAL BOARDS AND JOURNAL OVERSIGHT COMMITTEES

2018- Editor in Chief, ASN Neuro
2015-2017 Associate Editor, J. Neuroinflammation
2012-2017 Associate Editor, J. Neuroscience Research
1998-2017 Handling Editor, Journal of Neurochemistry
2009-2017 Handling Editor, ASN Neuro
2010-2017 Handling Editor, Metabolism
1999-2017 Handling Editor, Journal of Neuroimmunology
2009-2014 Handling Editor, Journal Neuroinflammation
2012-2014 Academic Editor, PLOS One
2008-2012 ASN Neuro Oversight Committee
2009-2011 Handling Editor, PPAR research
2002-2007 Handling Editor, Brain Research

CLINICAL TRIALS AND INDS

2018 Pre IND meeting for use of cholestyramine as countermeasure for BDF
2017 Pre IND meeting for use of intralipid as countermeasure for BDF
2004-2007 Director, Phase I Trial of Actos (Pioglitazone HCl) in RR-MS patients.
2006 Co-PI open label trial of Actos in Autistic Children
2007 PI of FDA approved IND to carry out Phase I trial of Actos in Autistic Children

SOCIETY MEMBERSHIPS

Society for Neuroscience (SFN), American Society for Neurochemistry (ASN), International Society for Neurochemistry (ISN); International Society for NeuroImmunology (ISNI)

AD HOC REVIEWER FOR

Journals: Am. J. Physiol., Brain Research, British J. Pharmacology, Cardiovascular Research, GLIA, J. Neurochem, J. Neuroscience, J. Cerebral Blood Flow and Metabolism, J. Neuroscience Research, J. Neuroimmunology, J. Immunology, J. Neuroinflammation, Life Sciences, Molecular Brain Research, Neuroscience Letters, PNAS

Granting Agencies: National Multiple Sclerosis Society; Ontario Mental Health Foundation, American Alzheimer's Association, Italian MS Society Medical Board, Irish Health Research Board, MS Society of the UK

Tenure Track Promotion Committees

Various universities including University of Manitoba, CA; University Wisconsin, Madison; Temple University, Philadelphia; University Rochester, NY; Case Western Reserve University School of Medicine, Cleveland; University California San Francisco, CA.

News and media coverage

2018 Coverage of the Synthetic Cannabinoid : brodifacoum crisis

Scientific American:

www.scientificamerican.com/article/the-spice-of-death-the-science-behind-tainted-synthetic-marijuana/

USA Today

www.usatoday.com/story/news/nation/2018/07/20/fda-warning-synthetic-marijuana-rat-poison/802585002/

2018 Coverage of alcohol effects on microglia and amyloid

Newsweek www.newsweek.com/drinking-alcohol-could-disrupt-cells-help-prevent-alzheimers-study-959279

Medscape www.medscape.com/viewarticle/898210

CITATIONS ANALYSIS

180 papers; 36 published, in press, or submitted 2014-2018.

H-index: 54 (Web of Science); H-index: 62 (Google Scholar); >13,000 citations (Google Scholar)

Full List Of Publications

www.ncbi.nlm.nih.gov/sites/myncbi/1xWLLti5v/bibliographay/40329176/public/?sort=date&direction=ascending

PUBLICATIONS

- 180 Moutal A, White KA, Chefdeville A, Laufmann R, Vitiello PF, **Feinstein DL**, Weimer K, and Khanna R (2019) Dysregulation of CRMP2 post-translational modifications drive its pathological functions. **Mol Neurobiol.** submitted
- 179 **Feinstein DL**, Gierzal K, Iqbal A, Kalinin S, Ripper R, Lindeblad M, van Breemen R, Weinberg G, Rubinstein I (2019) The relative toxicity of brodifacoum enantiomers. **Tox Letters**, *in press*
- 178 Lucia Lisi, Gabriella Maria Pia Ciotti, Marta Chiavari, Michela Pizzoferrato, Annunziato Mangiola, **Douglas L Feinstein** and Pierluigi Navarra (2018) Phospho-mTOR expression in human glioblastoma microglia cells. **ASN Neuro** in revision
- 177 Chase, K; Guizzetti, M; Kusumo, H; Khakhkhar, S; Kalinin, S; **Feinstein, DL**; Gavin, D (2019) Role of Poly ADP Ribose Polymerase (PARP) in Binge Alcohol Drinking. **Addiction Bio**, resubmitted
- 176 Rubinstein, I, Weinberg, G, van Breemen, R., Hershow, RC, **Feinstein, DL** (2018) Accelerated clearance of brodifacoum, a long-acting anticoagulant rodenticide, from poisoned patients with life-threatening bleeding. **Drug Safety R&D**, *in press*.
- 175 Rubinstein, I, **Feinstein, DL** (2018) Pesticide-Poisoned Patients: Can They Be Used as Potential Organ Donors? **J. Medical Toxicology**, 14(4):331-332. PMID: 30276621
- 174 Ruth N. Muchiri, Katarzyna E. Kowal, Kenneth Hensley, **Douglas L. Feinstein**, and Richard B. van Breemen (2018) Analysis of Lanthionine Ketimine and Ethyl Ester Derivatives in Mouse Serum, Whole Blood and Tissues using UHPLC-MS/MS. **Rapid Commun Mass Spec.** 32(22):1941-1948. PMID: 29897553
- 173 Rubinstein, I., Weinberg, G., van Breemen, R., Hershow, RC., **Feinstein, DL.** (2018) Treatment for long acting anticoagulant rodenticide poisoning – beyond INR monitoring? **Tox. Commun.** 2, 59-61.
- 172 Lindeblad M, Lyubimov A, van Breemen R, Gierszal K, Weinberg G, Rubinstein I, **Feinstein DL.** (2018) The bile sequestrant cholestyramine increases survival in a rabbit model of brodifacoum poisoning. **Toxicol Sci.** 165(2):389-395. PMID: 29897553
- 171 Irene L. Gutiérrez, Marta González-Prieto, Borja García-Bueno, Javier R. Caso, **Douglas L. Feinstein**, José L.M. Madrigal (2018) CCL2 induces the production of $\beta 2$ adrenergic receptors and modifies astrocytic responses to noradrenaline. **Molecular Neurobio**, 55(10):7872-7885. PMID: 29478130
- 170 Kalinin S, González-Prieto M, Scheiblich H, Lisi L, Kusumo H, Heneka MT, Madrigal JLM, Pandey SC, **Feinstein DL** (2018) Transcriptome analysis of alcohol treated microglia reveals inhibition of amyloid phagocytosis. **J. Neuroinflammation**, 15(1):141. **Altmetric score 191**
- 169 Dupree, JL, and **Feinstein, DL** (2018) Influence of diet on axonal damage in a mouse model of multiple sclerosis. **J. Neuroimmunology**, 322:9-14. PMID: 29759078
- 168 Marangoni NM, Kowal K, Deliu Z, Hensley K, and **Feinstein DL** (2018) Neuroprotective and neurotrophic effects of Lanthionine Ketimine Ester. **Neuroscience letters**, 664, 28-33.

- 167 David Braun, D. and **Feinstein, D.L.** (2017) The locus coeruleus neuroprotective drug vindaurnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer's disease. **Brain Res**, S0006-8993(17) 30563-2. doi: 10.1016/j.brainres.2017
- 166 Ware KM, **Feinstein DL**, Rubinstein I, Battula P, Otero J, Hebert L, Wang TF, Ivanova A, Chaudhary S, Hemminger J, Brodsky SV. (2017) The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data. **Stroke Res Treat**. PMID: 28808596
- 165 S Kalinin, N Marangoni, K Kowal, A Dey, K Lis, S Brodsky, R van Breemen, Z Hauck, R Ripper, G Weinberg, I Rubinstein, **DL Feinstein** (2017) Neuroinflammatory and neuropathological consequences of the long lasting rodenticide brodifacoum **Toxicol Sci**, 159(1): 224–237,
- 164 Changyaleketa, B., Deliu, Z., and **Feinstein, D.L.** (2017) Heparanase: Roles in Neurological Diseases and Conditions. **J. Neuroimmunology**, 310:72-81
- 163 Lisi L, Ciotti G.M.P. , Braun D, Kalinin S, Currò D, Dello Russo C, Lauriola L, Mangiola A, Anile C, **Feinstein DL**, Navarra P (2017) Microglial polarization in human glioblastoma. **Neuroscience Letters**, 645:106-112
- 162 **Feinstein, DL**, Brodsky, S, Weinberg, G, van Breeman, R and Rubinstein, I (2017) Brodifacoum poisoning: A clear and present danger to public health in the USA. **Toxicol Lett**. 268:71-72
- 161 Braun, D, Kalinin, S, and **Feinstein, D.L.** (2017) “Hippocampal BDNF depletion induces Locus Coeruleus damage and increases amyloid type pathology in 5xFAD mice” **ASN NEURO**, 9(2):1759091417696161
- 160 Marangoni MN, Braun D, Situ A, Moyano AL, Kalinin S, Polak P, Givogri MI, **Feinstein DL**. (2016) Differential effects on glial activation by a direct versus an indirect thrombin inhibitor. **J Neuroimmunol**. 297:159-68
- 159 Moyano, AL, Li, G., Boullerne, A., **Feinstein, DL**, Hartman, B, Skias, D. Balabanov, R., van Breemen, R., Bongarzone, E., Mansson, JE, and Givogri, MI (2016) Sulfatides in extracellular vesicles isolated from plasma of Multiple Sclerosis patients. **J. Neurosci. Res**, 94(12):1579-1587 PMID: 27557608
- 158 **Feinstein DL** et al. (2016) The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures. **Ann N Y Acad Sci**. 1374(1):111-22 PMID: 27244102
- 157 **Feinstein DL**, Skoff RP. (2016) Glial cell biology in the Great Lakes region. **J Neuroinflammation**. 13(1):69. PMID: 27029404
- 156 **Feinstein, DL** and Braun, D (2016) Causes, consequences and cures for neuroinflammation mediated via the Locus coeruleus: Noradrenergic signaling system. **J. Neurochem**. 139 Suppl 2:154-178. PMID: 26968403
- 155 Hauck, ZZ, **Feinstein, DL**, and van Breemen, R (2016) LC-MS/MS analysis of brodifacoum isomers in rat tissue. **J. Analytical Toxicology**, 40(4):304-9. PMID: 26968403
- 154 Marangoni N, Martynowycz MW, Weinberg G, Rubinstein I, Kuzmenko I, Gidalevitz D, Braun D, Polak PE, and **Feinstein DL** (2016) Membrane Cholesterol Modulates Superwarfarin Toxicity. **Biophys Journal**, 110(8):1777-88.
- 153 Ware, KM, **Feinstein, DL**, Rubinstein, I, Weinberg, G, Rovin, BH, Hebert, L, Muni, N, Cianciolo, RE, Satoskar, AA, Nadasdy, T, and Brodsky, SV (2015) BDF induces early hematuria and late hematuria in rats: Novel rapid biomarkers of poisoning. **American J Nephrology**, 41:392-399
- 152 Dupree, J, Hensley, K., Polak, PE, Pelligrino, D, and **Feinstein, DL** (2015) Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis **J. Neurochem**. 134(2):302-14.
- 151 Fettiplace MR, Pichurko A, Ripper R, Lin B, Kowal K, Lis K, Schwartz D, **Feinstein DL**, Rubinstein I, Weinberg G. (2015) Cardiac depression induced by cocaine or cocaethylene is alleviated by lipid emulsion more effectively than by sulfobutylether- β -cyclodextrin. **Acad Emerg Med**. 22(5):508-17.
- 150 Boullerne, AI, Polak, PE, Hartman, E., Testai, F; Skias, D., and **Feinstein, DL** (2015) A single nucleotide polymorphism in Liver Kinase B1 is a risk factor for multiple sclerosis. **ASN NEURO**, 18;7(1).
- 149 Heneka et al (2015) Neuroinflammation in Alzheimer's disease. **Lancet Neurology**, 14(4):388-405
- 148 Braun D, Madrigal JM, **Feinstein DL** (2014) Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications. **Current Neuropharmacology**, 12(4):342-52
- 147 Polak, PE, Lin SX, Pelligrino D, **Feinstein DL** (2014) The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis. **J. Neuroimmunology**, 276 (1-2), 135-141. PMID: 25242632
- 146 Boullerne AI, Polak PE, Braun D, Sharp A, Pelligrino D, **Feinstein DL**. (2014) Effects of peptide fraction and counter ion on the development of clinical signs in experimental autoimmune encephalomyelitis. **J Neurochem**. 129(4):696-703. PMID: 24471474
- 145 Fettiplace MR, Ripper R, Lis K, **Feinstein DL**, Rubinstein I, Weinberg G. (2014) Intraosseous lipid emulsion: an effective alternative to IV delivery in emergency situations. **Crit Care Med**. 42:e157-60. PMID: 24145832
- 144 Ghods AJ, Glick R, Braun D, **Feinstein D.** (2013) Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas. **Surg Neurol Int**. 4:160. PMID: 24404403
- 143 Kalinin S, Polak PE, Lin SX, Braun D, Guzzetti M, Zhang X, Rubinstein I, and **Feinstein DL** (2013) Dimethyl fumarate regulates histone deacetylase expression in astrocytes. **J. Neuroimmunol** 15;263. PMID: 23916696
- 142 Kalinin S, Willard SL, Shively CA, Kaplan JR, Register T, Jorgensen MJ, Rubinstein I, and **Feinstein DL** (2013) Development of amyloid burden in African green monkeys. **Neurobiology of Aging**, 34(10):2361-9
- 141 Hvaring C, Vujicic S, Aasly JO, **Feinstein DL**, White LR, Boullerne AI. (2013) IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis. **J Neuroimmunol**. 256(1-2):77-83

- 140 Polak PE, Dull RO, Kalinin S, Sharp AJ, Ripper R, Weinberg G, Schwartz DE, Rubinstein I, **Feinstein DL** (2012) "Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis" **J Neuroinflammation** 9(1):272
- 139 Lisi L, McGuire S, Sharp A, Chiosis G, Navarra P, **Feinstein DL**, Dello Russo C (2012) "The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE" **J Neuroimmunol.** 255(1-2):1-7.
- 138 Dello Russo C, Lisi L, **Feinstein DL**, Navarra P. (2012) "mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis". **GLIA** 61(3):301-11.
- 137 Krishnamoorthy V, Hiller DB, Ripper R, Lin B, Vogel SM, **Feinstein DL**, Oswald S, Rothschild L, Hensel P, Rubinstein I, Minshall R, Weinberg GL. (2012) "Epinephrine Induces Rapid Deterioration in Pulmonary Oxygen Exchange in Intact, Anesthetized Rats: A Flow and Pulmonary Capillary Pressure-dependent Phenomenon. **Anesthesiology** 117(4):745-754
- 136 Colca JR, **Feinstein DL**. (2012) "Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease" **Adv Pharmacol.** 64:155-76.
- 135 Xin J, **Feinstein DL**, Hejna MJ, Lorens SA, McGuire SO. (2012) "Beneficial Effects of Blueberries in Experimental Autoimmune Encephalomyelitis." **J Agric Food Chem.** 60(23):5743-48
- 134 Kalinin S, Polak PE, Lin SX, Sakharkar AJ, Pandey SC, **Feinstein DL**. (2012) "The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease." **Neurobiol Aging.** 33(8):1651-63
- 133 Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, **Feinstein DL**, Dello Russo C. (2012) "Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis." **J Neuroimmunol.** 243(1-2):43-51
- 132 Polak PE, Kalinin S, Braun D, Sharp A, Lin SX, **Feinstein DL**. (2012) "The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus". **J Neurochem.** 121(2):206-16.
- 131 Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, Weinberg G, Kalinin S, **Feinstein DL** (2011) "The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and heme-oxygenase1" **ASN NEURO** E00055
- 130 Pifarre P, Prado J, Baltrons MA, Giralt M, Gabarro P, **Feinstein DL**, Hidalgo J, Garcia A (2011) Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. **Acta Neuropathol.** 121(4):499-508.
- 129 Polak PE, Kalinin S, **Feinstein DL** (2011) Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. **Brain.** 134(Pt 3):665-77.
- 128 Lisi L, Navarra P, **Feinstein DL**, Dello Russo C. (2011) The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. **J Neuroinflammation.** 8(1):1
- 127 Weinberg, G, Ripper, R, and **Feinstein, DL**. (2011) "Pioglitazone Attenuates Acute Cocaine Toxicity in Rat Isolated Heart: Potential Protection by Metabolic Modulation" **Anesthesiology**, 114(6):1389-95.
- 126 Ksendzovsky A, Glick RP, Polak P, Simonini MV, Sharp AJ, Newman T, Cohen E, and Feinstein DL (2010) "Mechanisms of Cytokine-Induced Glioma Immunosuppression" **Open Cancer Immunology**, 3:30-35.
- 125 Akar, C, Gavriilyuk, V, Spagnolo, A, Weinberg, G and **Feinstein, DL** (2010) Receptor-independent metabolic effects of thiazolidinediones in astrocytes; **Open Cancer Immunology**, 3:36-40.
- 124 Weinberg, G, Lin B, Zheng, S, DiGregorio G, Hiller D, Ripper R, Edelman L, Kelly K, and Feinstein DL (2010) "Partitioning effect in lipid resuscitation: further evidence for the lipid sink" **Crit Care Med** 38 (11), 2268-69.
- 123 Shukla, DK; Kaiser, CC; Stebbins, GT; and **Feinstein, DL** (2010) "Effects of Pioglitazone on Diffusion Tensor Imaging Indices in Multiple Sclerosis Patients" **Neurosci Lett.** 472(3):153-6. Epub 2010 Feb 6.
- 122 Madrigal, J.L.M., Garcia-Bueno, B., **Feinstein, DL** and Leza, JC (2010) Regulation of MCP-1 expression in brain by stress and noradrenergic tone. **J. Neurochemistry**, Apr 1;113(2):543-51. Epub 2010 Jan 28.
- 121 Simonini, MV, Polak, PE, Boullerne, AI., Peters, JM., Richardson, JC, and **Feinstein, DL** (2010) Regulation of Oligodendrocyte Progenitor Cell Maturation by PPARdelta and Effects on Bone Morphogenetic Protein Signaling **ASN Neuro.** 2(1):e00025.
- 120 Simonini, MV; Polak PE; Sharp, A.; McGuire, S.; Galea, E.; and **Feinstein, DL** (2010) Increasing Central Noradrenaline Reduces EAE Severity, **J Neuroimmune Pharmacol.** 5(2):252-9. Epub 2009 Dec 4.
- 119 Hiller DB, Gregorio GD, Ripper R, Kelly K, Massad M, Edelman L, Edelman G, **Feinstein DL**, Weinberg GL. (2009) Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. **Anesthesiology.** 111(3):498-505.
117. Kalinin, S; Richardson, JC, and **Feinstein, DL** (2009) "A PPARdelta Agonist Reduces Amyloid Burden and Brain Inflammation in Transgenic Mouse Model of Alzheimer's Disease." **Current Alzheimer's Research**, 6(5):431-7.
- 116 C.C. Kaiser; D.D. Skias; D.K. Shukla; G.T. Stebbins; D.R. Jeffery; D. Stefoski; G. Katsamakias; **D.L. Feinstein** (2009) A placebo-controlled randomized trial of Pioglitazone as add-on in Relapsing Remitting MS Patients, **J. Neuroimmunology**, 211(1-2):124-30
- 115 Akar, C. and **Feinstein, D.L.** (2009) "SUMOylation regulates Nitric Oxide Synthase Expression in Astrocytes" **J. Neuroinflammation**, 6:12.
- 114 Madrigal JL, Leza JC, Polak P, Kalinin S, **Feinstein DL**. (2009) "[Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline.](#)" **J Neurosci.** 29(1):263-7. PMID: 19129402

- 113 Di Gregorio G, Schwartz D, Ripper R, Kelly K, Feinstein DL, Minshall RD, Massad M, Ori C, Weinberg GL. (2009) Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. **Crit Care Med.** 37(3):993-9.
- 112 Ksendzovsky, A., Zengou, R., Sharp, A., Polak, P.E., Feinstein, D.L., Lichtor, T., and Glick, R.P. (2009) Investigation of immunosuppressive mechanisms in a mouse glioma model **J. Neuro-oncology**, 93(1):107-14..
- 111 Sharp, A, Polak PE, Xia-Lin, S, Simonini V, Richardson JC, and Feinstein DL (2008) "The P2x7 receptor is critical for development of disease in an animal model of Multiple Sclerosis" **J Neuroinflamm.**5(1):33.
- 110 Siegel GJ, Chauhan NB, Feinstein DL, Li G, Larson EB, Breitner JC, Montine TJ. (2008) Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. **Neurology** . Jul 29;71(5):383
- 109 Feinstein, DL, Spagnolo, A, and Dello-Russo, D. (2007) "Neuroprotective Features of Hsp90 Inhibitors Exhibiting Anti-Inflammatory Actions: Implications for Multiple Sclerosis" in Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection, Springer Publisher, Alexzander A.A. Asea (Author, Editor), Ian R. Brown (Editor)
- 108 Lichtor T, Spagnolo A, Glick R, and Feinstein DL. (2008) "PPAR-gamma Thiazolidinedione Agonists and Immunotherapy In the Treatment of Brain Tumors" **PPAR Research**, April 2008, 547470,
- 107 Weinberg, GL, DiGregorio G, Ripper R, Kelly K, Massad M, Edelman L, Schwartz D, Shah N, Zheng S, DL Feinstein (2008) Resuscitation with Lipid versus Epinephrine in a Rodent Model of Bupivacaine-Induced Asystole **Anesthesiology** May;108(5):907-13.
- 106 Madigal, JLM, Kalinin, S, and Feinstein, DL (2007) "Neuroprotective Actions of Noradrenaline: Effects on Glutathione Synthesis and Activatin of Peroxisome Proliferator Activated Receptor Delta" **J. Neurochem** 103(5):2092-101.
- 105 Spagnolo A., Glick RP, Lichtor T, and Feinstein, DL (2007) "Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes" **Neurosci. Lett.** 417(1):72-7.
- 104 Tureyen K, Kapadia R, Bowen KK, Liang J., Feinstein DL and Vemuganti V (2007) "Peroxisome proliferator activated-receptor- γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents" **J. Neurochem**, 101(1):41-56.
- 103 Spagnolo A, Glick RP, Lin H, Cohen EP, Feinstein DL, and Lichtor T (2007) Prolonged Survival of Mice with Established Intracerebral Glioma Receiving Combined Treatment with PPAR- γ Thiazolidinedione Agonists and IL-2 Secreting Syngeneic/Allogeneic Fibroblasts. **J. Neurosurgery** 106(2):299-305.
- 102 Perez FP, Ilie JI, Zhou X, Feinstein D, Jurivich DA. (2007) Pathomolecular effects of homocysteine on the aging process: A new theory of aging. **Med Hypotheses.** 69(1):149-60
- 101 Kalinin S, Gavrilyuk V, Polak PE, Heneka MT, and Feinstein DL (2007) "Noradrenaline deficiency in brain increases β -amyloid plaque burden in an animal model of Alzheimer's disease" **Neurobio Aging**, 28(8):1206-14
- 100 Boris M, Kaiser C, Golblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. (2007) Effect of pioglitazone treatment on behavioral symptoms in autistic children. **J Neuroinflammation.** 4(1):3
- 99 Kalinin S, Feinstein DL, Xu HL, Huesa G, Pelligrino DA, Galea E. (2006) "Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain" **Eur J Neurosci.** 24(12):3393-400.
- 98 Phulwani NK, Feinstein DL, Akar C, Gavrilyuk V, and KielianT (2006) 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ and ciglitazone modulate astrocyte activation through PPARg-independent pathways **J.Neurochem** 99(5):1389-1402
- 97 Galea E, Feinstein DL, and Lacombe P (2006) Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice **Diabetologia** 49(9):2153-61
- 96 Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH , Schlegel A, and Heneka MT (2006) "Inhibition of in vivo glioma growth and invasion by PPAR γ agonist treatment" **Mol Pharm.** 70(5):1524-33.
95. Dello Russo, C, Mercado PR, Sharp A, Polak PE, Kamal A, Burrows F, and Feinstein, DL. (2006) The HSP90 Inhibitor 17-AAG Suppresses Glial Inflammatory Responses and Reduces Experimental Autoimmune Encephalomyelitis. **J. Neurochemistry**, 99(5):1351-1362.
- 94 Stankoff B, Wang Y, Bottlaender M, Aigrot MS, Dolle F, Wu C, Feinstein DL, Huang GF, Semah F, Mathis CA, Klunk W, Gould RM, Lubetzki C, Zalc B. (2006) Imaging of CNS myelin by positron emission tomography (PET) **Proc Natl Acad Sci** 103(24):9304-9.
- 93 Wu C, Tian D, Feng Y, Polak P, Wei J, Sharp A, Stankoff B, Lubetzki C, Zalc B, Mufson E, Gould R, Feinstein DL, and Wang Y. (2006) A Novel Fluorescent Probe that is Brain Permeable and Selectively Binds to Myelin. **Journal of Histochemistry & Cytochemistry** 54(9):997-1004.
92. Weinberg GL, Ripper R, Murphy P, Edelman LB, Hoffman W, Strichartz G, and Feinstein DL (2006) Lipid Infusion Accelerates Removal of Bupivacaine and Recovery from Bupivacaine Toxicity in the Isolated Rat Heart **Regional Anesthesiology & Pain Medicine.** Jul-Aug;31(4):296-303.
91. Ross JD, Ripper R, Law WL, Massad M, Murphy P, Edelman L, Conlon B, Feinstein DL, Palmer JW, DiGregorio G, and Weinberg G (2006) Adding Bupivacaine to High-Potassium Cardioplegia Improves Function and Reduces Cellular Damage of Rat Isolated Hearts After Prolonged Cold Storage **Anesthesiol.**, 105(4):746-52.
90. Bhat NR and Feinstein DL. (2006) "NO and Glial Cell Biology" **Antioxid & Redox Signal.** 8(5-6):869-72.
89. Madrigal, JLM, Dello Russo C, Gavrilyuk V, and Feinstein DL (2006) "Effects of Noradrenaline on Neuronal NOS2 Expression and Viability", **Antioxidant & Redox Signaling**, 8(5-6):885-92.

88. Kalinin S, Polak PE, Madrigal JL, Gavrilyuk V, Sharp A, Chauhan N, Marien M, Colpaert F, Feinstein DL. (2006) "Beta-Amyloid Dependent Expression of Inducible Nitric Oxide Synthase in Neurons: Prevention by an α 2-Adrenergic Receptor Antagonist" **Antioxidant & Redox Signaling**, 8(5-6):873-33.
87. Polak, P., Kalinin, S., Dello Russo, C., Gavrilyuk, V., Sharp, A., Peters, J.M., Richardson, J., Willson, T.M., Weinberg, G., Feinstein, D.L. (2005) Protective Effects of a Peroxisome Proliferator-Activated Receptor-b/d Agonist in Experimental Autoimmune Encephalomyelitis. **J. Neuroimmunology**, 168(1-2):65-75.
86. Xu HL, Ye S, Baughman VL, Feinstein DL, Pelligrino DA. (2005) The role of the glia limitans in ADP-induced pial arteriolar relaxation in intact and ovariectomized female rats. **Am J Physiol Heart Circ Physiol**. 288(1):H382-8.
85. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V. and Dello Russo C. (2005) "Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?" **Biochem. Pharmacology**, 70(2):177-88.
84. Gavrilyuk V, Kalinin S, Hilbush BS, Middlecamp A, McGuire S, Pelligrino D, Weinberg G, and Feinstein DL (2005) "Identification of a Complement 5a-Like Receptor from Astrocytes: Characterization of Anti-Inflammatory Properties", **J. Neurochem**. 92(5):1140-9.
83. Madrigal, JMM, Feinstein, DL, and Dello Russo, C (2005) "Norepinephrine protects cortical neurons against microglial-induced cell death", **J. Neurosci. Research**, 81(3):390-6..
82. Chauhan NB, Siegel GJ, and Feinstein DL (2005) "Effect of Propentofylline on Amyloid Plaque and Neurofibrillary Tangle Pathology in Tg2576 Mouse Model of Alzheimer's Disease" **Neuropharmacology**;48(1):93-104.
81. Feinstein, D.L. (2004) "Contrasting the Neuroprotective and Gliotoxic Effects of PPAR γ agonists" **Drug Discovery Today, Therapeutic Strategies** 1(1); 29-34. **Invited Review**
80. Chauhan NB, Siegel GJ, and Feinstein DL (2004) "Effects of Lovastatin and Pravastatin on Cerebral Amyloid Processing and Inflammatory Response in TgCRND8 Brain" **Neurochem Res**. 29(10):1897-911.
79. Lacombe P, Mathews PM, Schmidt SD, Breidert T, Heneka MT, Landreth GE, Feinstein DL, Galea E. (2004) "Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised" **J. Neuroinflammation** 1:11
78. Dello Russo, C, Boullerne AI, Gavrilyuk V, and Feinstein DL (2004) Inhibition of microglial inflammatory responses by norepinephrine: effects on IL-1 β and NO production. **J. Neuroinflammation** 1:9.
77. Pershadsingh, HA, Schmidt, S, Heneka, MT, Feinstein, DL. (2004) "Pioglitazone treatment in a patient with secondary multiple sclerosis" **J. Neuroinflammation** 1:3.
76. Weinberg G, Paisanthasan C, Feinstein D, Hoffman W. (2004) "The effect of bupivacaine on myocardial tissue hypoxia and acidosis during ventricular fibrillation" **Anesth Analg**. 98(3):790-5.
75. Xu HL, Koenig HM, Ye S, Feinstein DL, Pelligrino DA. (2004) "Influence of the glia limitans on pial arteriolar relaxation in the rat" **Am J Physiol Heart Circ Physiol** Am J Physiol Heart Circ Physiol. Jul;287(1):H331-9.
74. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. (2004) Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. **J Leukoc Biol**. Mar;75(3):478-85
73. Klotz, L., Sastre, M., Kreutz, A., Gavrilyuk, V., Klockgether, T., Feinstein, D.L., and Heneka, M.T. (2003) "Noradrenaline-induced expression of peroxisome proliferator activated receptor gamma (PPAR γ) in murine primary astrocytes and neurons" **J. Neurochem**. 86(4):907-16.
72. Weinberg, G., Ripper, R., Feinstein, D.L., and Hoffman, W. (2003) "Lipid Emulsion Infusion Rescues Dogs from Bupivacaine-Induced Circulatory Collapse", **Regional Anesthesia and Pain Medicine**, 28(3):198-202.
71. Heneka, MT, Gavrilyuk, V, Landreth, GE, O'Banion, MK, Weinberg, G, and Feinstein, DL (2003) "Noradrenergic depletion increases inflammatory responses in brain: Effects on I κ B and HSP70" **J Neurochem**. 2003 Apr;85(2):387-98.
70. Dello Russo, C., Galea, E., Gavrilyuk, V., Weinberg, G., Palmer, J., Almeida, A., Bolanos, J.P., Pelligrino, D., and Feinstein, D.L. (2003) "PPAR γ agonists increase glucose metabolism in Astrocytes" **J Biol Chem**. 278(8):5828-36.
69. Feinstein, D.L. (2003) "Therapeutic Potential of PPAR Agonists for Neurological Disease" **Diabetes Technology and Therapeutics**, 5(1):67-73. **Invited Review**
68. Duvanel, C.B., Honegger, P., Pershadsingh, H., Feinstein, D., and Matthieu, J.-M. (2003) "Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro" **J. Neurosci. Res**. 71(2):246-55.
67. Galea, E., Heneka, M.T., Dello Russo, C., and Feinstein, D.L. (2003) "Intrinsic Regulation of Brain Inflammatory Responses" **Cell Molec. Neurobiology**, Review, 23(4,5): 625-635. **Invited Review**
66. Galea E, Santizo R, Feinstein DL, Adamsom P, Greenwood J, Koenig HM, Pelligrino DA. (2002). "Estrogen inhibits NF κ B-dependent inflammation in brain endothelium without interfering with I κ B degradation. **Neuroreport** 13:1469-72.
65. Bhat NR, Feinstein DL, Shen Q, Bhat AN. (2002) "p38 MAPK-mediated transcriptional activation of inducible nitric oxide synthase in glial cells: Roles of nuclear factors, NF κ B, CREB, C/EBP and ATF2" **J. Biol. Chem**. 277(33):29584-92.

- 64 Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsnecht J, Heneka MT. (2002) "Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR γ " **J Neurochem**, 81, 1052–1060
- 63 Gavriluyk V, Dello Russo C, Heneka MT, Pelligrino D, Weinberg G, Feinstein DL (2002) "Norepinephrine Increases I κ B α Expression in Astrocytes" **J. Biol. Chem.** 277(33):29662-8.
- 62 Feinstein DL, Galea E, Gavriluyk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. (2002) "Prevention and treatment of experimental autoimmune encephalomyelitis by pioglitazone, a PPAR- γ agonist" **Annals Neurology**, 51(6):694-708.
- 61 Heneka MT, Galea E, Gavriluyk V, Dumitrescu-Ozimek L, Daeschner J, O'Banion MK, Weinberg G, Klockgether T, Feinstein DL. (2002) "Noradrenergic depletion potentiates β -amyloid induced inflammation in frontal cortex: Implications for Alzheimer's disease" **J. Neuroscience**, 22(7):2434-42.
- 60 Zekki, H., Feinstein, D.L., and Rivest, S. (2002) "The clinical course of experimental autoimmune encephalomyelitis is associated with transcriptional activation of Toll-like receptor 2 and CD14 in the mouse CNS", **Brain Pathology** 12(3):308-19.
- 59 Feinstein D, Heneka M, Gavriluyk V, Russo C, Weinberg G, Galea E. (2002) "Noradrenergic regulation of inflammatory gene expression in brain. **Neurochem Int.** 41:357. **Invited Review**
- 58 Murphy P, Sharp A, Shin J, Gavriluyk V, Dello Russo C, Weinberg G, Sharp FR, Lu A, Heneka MT, Feinstein DL. (2002) "Suppression of Inducible Nitric Oxide Synthase Expression in Glial Cells by Ansamycins" **J. Neuroscience Res** 67, 461-470
- 57 Xu HL, Feinstein DL, Santizo RA, Koenig HM, Pelligrino DA. (2002) Agonist-specific differences in mechanisms mediating eNOS-dependent pial arteriolar dilation in rats. **Am J Physiol Heart Circ Physiol.** 282(1):H237-H243.
- 56 Gavriluyk V, Horvath P, Weinberg G, Feinstein DL. (2001) "A 27 bp region of the rat Nitric Oxide Synthase Type 2 promoter confers sensitivity to inhibition by cAMP" **J. Neurochemistry**, 78, 129-141.
- 55 Zander T, Kraus JA, Schlegel U, Feinstein DL, Klockgether T, Heneka MT (2001) PPAR γ -mediated apoptotic cell death in human and rat glioma cell lines: A new therapeutic strategy? **Neurology** 56 (8): A480-A481
- 54 Heneka MT, Wiesinger H, Dumitrescu-Ozimek L, Riederer P, Feinstein DL, Klockgether T. (2001) Neuronal and glial coexpression of argininosuccinate synthase and inducible nitric oxide synthase in Alzheimer disease. **J. Neuropathol & Exp. Neurol.** 60, 906–916.
- 53 Heneka MT, Feinstein DL. (2001) "Expression and function of the inducible Nitric Oxide Synthase in neurons", **J. Neuroimmunology**, 114(1-2):8-18. **Invited Review**
- 52 Feinstein, D.L., Murphy, P., Sharp, A., Galea, E., Gavriluyk, V., and Weinberg, G. (2001) "Local Anesthetics Potentiate Nitric Oxide Synthase Type 2 Expression in Rat Glial Cells" **J Neurosurg Anesthesiol.** 13(2):99-105.
- 51 Heneka, M.T., Landreth, G.E., and Feinstein, D.L. (2001) "A role for peroxisome proliferator-activated receptor- γ in Alzheimer's disease" **Annals of Neurology**, 2, 276.
- 50 Heneka, M.T., Sharp, A., Murphy, P., Lyons, J.-A., Dumitrescu, L. and Feinstein, D.L. (2001) "The Heat Shock Response prevents MOG induced Experimental Allergic Encephalomyelitis" **J Neurochem.** 77(2):568-579.
- 49 Gould, R.M., Freund, C.M., Palmer, F. and Feinstein, D.L. (2000) "Messenger RNAs located in myelin sheath assembly sites" **J. Neurochemistry**, 75, 1834.
- 48 Heneka, M.T., Klockgether, T., and Feinstein, D.L. (2000) "Peroxisome proliferator-activated receptor gamma agonists reduce inducible nitric oxide synthase expression in cerebellar granule neurons in vivo" **J. Neuroscience**, 20, 6862.
- 47 Pelligrino D.A., Ye S., Tan F., Santizo R.A., Feinstein, D.L., and Wang Q. (2000) Nitric-oxide-dependent pial arteriolar dilation in the female rat: effects of chronic estrogen depletion and repletion. **Biochem Biophys Res Commun.** 269:165-71.
- 46 Stasiolek, M., Gavriluyk, V., Sharp, A., Selmaj, K., and Feinstein, D.L. (2000) "Lactacystin inhibits astroglial Nitric Oxide Synthase type 2: effects on I κ B- β expression" **J. Biol. Chem.** 275, 24847-24856
- 45 Heneka, M.T., Sharp, A., Gavriluyk, V., Klockgether, T., and Feinstein, D.L. (2000) "The heat shock response inhibits NOS2 expression and leukocyte infiltration in brain" **J. Cereb. Blood Flow Metab.** 20, 800-811.
- 44 Galea, E., Bhat, N.R. and Feinstein, D.L. (2000) "Transcriptional regulation of the Inflammatory Nitric Oxide Synthase Gene: convergence of cytosolic and nuclear signals." **Electronic Journal of Pathology and Histology**, volume 5, number 5. **Invited Review**
- 43 Heneka, M.T., Feinstein, D.L., Galea, E., Wüllner, U. and Klockgether, T. (1999) "PPAR γ -agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase" **J. Neuroimmunology**, 100, 158-167.
- 42 Gould, R., Knapp, P.E., Huang, J., Morrison, H., and Feinstein, D.L. (1999) "Messenger RNAs for kinesins and dynein are located in neural process" **Biol. Bull.** 197, 259-260.
- 41 Galea, E. and Feinstein, D.L. (1999) "Regulation of Nitric Oxide Synthase expression by Cyclic AMP" **FASEB J.** 13, 2125. **Review**
- 40 Regunathan, S., Feinstein, D.L., and Reis, D.J. (1999) "Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are receptors involved?" **Ann. N. Y. Acad. Sci.** 881:410-9
- 39 Feinstein, D.L., Regunathan, S., and Reis, D.J. (1999) "Inhibition of Astroglial Nitric Oxide Synthase Type 2 Expression by Idazoxan" **Molecular Pharm.** 55, 304-308.

- 38 Galea, E., Glickstein, S.B., Feinstein, D.L., Golanov, E., and Reis, D.J. (1998) "Cerebellar stimulation inhibits Interleukin 1- β cerebrovascular inflammation" **Am. J. Physiol.** 275 H2053-2063.
- 37 Lacroix, S., Feinstein, D., and Rivest, S. (1998) "Bacterial endotoxin LPS has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations" **Brain Pathol.** 8, 625-640.
- 36 Galea, E., Golanov, E.V., Feinstein, D.L., Kobylarz, K., Glickstein, S.B., and Reis, D.J. (1998) "Cerebellar stimulation reduces inducible nitric oxide synthase expression and protects brain from ischemia" **Am. J. Physiol.** 274, H2035-H2045.
- 35 Feinstein, D.L. (1998) "Lithium Increases Rat Astroglial Nitric Oxide Synthase Type-2 Expression" **J. Neurochem.** 71, 883-886.
- 34 Feinstein, D.L. (1998) "Norepinephrine Suppresses Astroglial Inducible Nitric Oxide Synthase Induction by Reducing Transcription from the NOS-2 Promoter" **J. Neurochem.** 70, 1484-1496.
- 33 Sastre, M., Galea, E., Feinstein, D., Reis, D.J., and Regunathan, S. (1998) "Metabolism of agmatine in macrophages: modulation by lipopolysaccharide and inhibitory cytokines" **Biochem J.** 330, 1405-1409.
- 32 Reis, D.J., Golanov, E.V., Galea, E., and Feinstein, D.L. (1997) "Central neurogenic neuroprotection: central neural systems that protect the brain from hypoxia and ischemia." **Ann. N. Y. Acad. Sci.** 835, 168-186.
- 31 Feinstein, D.L., Galea, E., and Reis, D.J. (1997) "Suppression of Glial Nitric Oxide Synthase Induction by Heat Shock: Effects on Proteolytic Degradation of I κ B- α " **Nitric Oxide: Chem. and Biol.** 2, 167-176.
- 30 Militante, J.D., Feinstein, D.L., and Syapin, P.J. (1997) "Suppression by Ethanol of Inducible Nitric Oxide Synthase Expression in C6 Glioma Cells" **J. Pharm. Exper. Therap.** 281, 558-565.
- 29 Feinstein, D.L. and Rozelman, E. (1997) "Norepinephrine Suppresses L-Arginine Uptake in Rat Glial Cells" **Neurosci. Lett.** 223, 37-40.
- 28 Feinstein, D.L., Galea, E., Aquino, D.A., Li, G.C., Xu, H., and Reis, D.J. (1996) "Heat Shock Protein 70 Suppresses Astroglial Inducible Nitric Oxide Synthase Expression by Blocking NF κ B Activation" **J. Biol. Chem.** 271 (30): 17724-17732.
- 27 Weng, G.Z., Feinstein, D., Reis, D. and Wahlestedt, C. (1996) Neuropeptide Y receptor gene regulation in mouse adrenocortical Y-1 cells" **Regul. Pept.** 63, 53-56.
- 26 Galea, E., Regunathan, S., Eliopoulos, V., Feinstein, D.L., and Reis, D.J. (1996) "Inhibition of Mammalian Nitric Oxide Synthases by Agmatine, an Endogenous Decarboxylated Arginine", **Biochem J.** 316: 247-249.
- 25 Galea, E., Fox, E., Reis, D.J., Xu, H., and Feinstein, D.L. (1996) "CD14 mediates Glial Nitric Oxide Synthase Induction by Lipopolysaccharide", **J. Neuroimmunology** ,64, 19-28.
- 24 Feinstein, D.L., and Apatoff, B.R. (1995) "Inducible Nitric oxide synthase expression in multiple sclerosis brain" **Neurology** 45 (4) A467.
- 23 Galea, E., Reis, D.J., and Feinstein, D.L. (1995) "Transient Expression of Calcium Independent Inducible Nitric Oxide Synthase in Blood Vessels during Brain Development", **FASEB J.**, 9. 1632-1637.
- 22 Galea, E., Reddi, J., and Feinstein, D.L. (1995) "Differential Inhibition of Inducible Nitric Oxide Synthase by Tyrphostins" **Neurosci Lett.** 200, 195-198.
- 21 Regunathan, S., Feinstein, D.L., Raasch, W., and Reis, D.J. (1995) "Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes". **Neuroreport** 6, 1897-1900.
- 20 Galea, E., Dupouey, P., and Feinstein, D.L. (1995) "Glial Gibrillary Acidic Protein mRNA Isoforms: Expression in vitro and in vivo", **J. Neurosci. Res.** 41, 452-461.
- 19 Galea, E., Reis, D.J., and Feinstein, D.L. (1994) "Cloning and expression of Astroglial Inducible Nitric Oxide Synthase" **J. Neurosci. Res.** 37, 406-411.
- 18 Feinstein, D.L., Galea, E., Cermak, J., Chugh, P., Lyandvert, L., and Reis, D.J. (1994) "Tyrosine Kinase Inhibitors Block Nitric Oxide Synthase Induction in Glial Cells", **J. Neurochem.** 62, 811-814.
- 17 Feinstein, D.L., Galea, E., Roberts, S., Berquist, H., Wang, H., and Reis, D.J. (1994) "Induction of Nitric Oxide Synthase in Rat C6 Glioma Cells" **J. Neurochem.** 62, 315-321.
- 16 Reis, D.J., Regunathan, S., Golanov, E.V., and Feinstein, D.L. (1994) "Protection of focal ischemic infarction by rilmenidine: Evidence that interactions with central imidazoline receptors may be neuroprotective. **Am J. Cardiol.** 74, A25-A30.
- 15 Murphy, S., Simmons, M.L., Agullo, L., Garcia, A., Feinstein, D.L., Galea, E., Reis, D.J., Minc-Golomb, D., and Schwartz, J.P. (1993) Synthesis of Nitric Oxide in CNS Glial Cells" **Trends in Neurosci.**, 16, 323-328.
- 14 Feinstein, D.L., Galea, E., and Reis, D.J. (1993) "Norepinephrine inhibits Nitric Oxide Synthase Induction in Rat Astrocyte Cultures" **J. Neurochem.**, 60, 1945-1948.
- 13 Regunathan, S., Feinstein, D.L., and Reis, D.J. (1993) "Rat Cerebral Cortical Astrocytes, but not Neurons, Express Functional Imidazoline Receptors", **J. Neurosci. Res.**, 34, 681-688.
- 12 Galea, E., Feinstein, D.L., and Reis, D.J. (1992) "Induction of Nitric Oxide Synthase Activity in Primary Cultures of Rat Brain Astrocytes", **Proc. Natl. Acad. Sci.**, 89, 10945-10949.
- 11 Galea, E. and Feinstein, D.L. (1992) "Rapid Synthesis of DNA Deletion Constructs for mRNA Quantitation: Analysis of Astrocyte mRNAs". **PCR Methods and Appl.**, 2, 66-69

- 10 Martin, J.-L., Feinstein, D.L., Yu, N., Sorg, O., Rossier, C., and Magistretti, P.J. (1992) "VIP Receptor Subtypes in Mouse Cerebral Cortex: Evidence for Differential Localization in Astrocytes, Microvessels, and Synaptosomal Membranes" **Brain Res.**, 587, 1-12.
- 9 Feinstein, D.L., G. Weinmaster, and R. J. Milner (1992) "cDNA clones encoding rat Glial Fibrillary Acidic Protein: Expression in astrocytes and Schwann cells." **J. Neurosci. Res.**, 32, 1-14.
- 8 Feinstein, D.L., Mumby, S., and R.J. Milner (1992) "Characterization of Gsa mRNA transcripts in primary cultures of rat brain astrocytes" **Glia** 5, 139-145.
- 7 Feinstein, D.L., Durand, M., and R.J. Milner (1991) "Expression of Myosin Regulatory Light Chains in Rat Brain: Characterization of a Novel Isozyme" **Mol. Brain Res.** 10, 97-105.
- 6 Feinstein, D.L. and Larhammar, D. (1990) "Identification of a Conserved Protein Motif in a Group of Growth Factor Receptors" **FEBS Lett.** 272, 7-11.
- 5 Mokuno, K., Kamholz, J., Behrman, T., Black, C., Feinstein, D.L., Lee, V., and Pleasure, D. (1989) "Neuronal Modulation of Schwann Cell Glial Fibrillary Acidic Protein" **J. Neurosci. Res.** 23, 396.
- 4 Feinstein, D.L. and Moudrianakis, E.N.M. (1986) "Thiol Reactivity of Histone H3 in Soluble and DNA-Associated Histone Complexes: Evidence for Allosteric and Torsional Regulation" **Biochem.** 25, 8409.
- 3 Feinstein, D.L. and Moudrianakis, E.N.M. (1984) "Response of the Adenosine Triphosphatase Activity of the Soluble Latent F1 Enzyme from Beef Heart Mitochondria to Changes in Mg⁺ and H⁺ Concentrations" **J. Biol. Chem.** 259, 4230.
- 2 Feinstein, D.L. and Moudrianakis, E.N.M. (1984) "Hydrophobic and Ionic Effects upon the Electrophoretic Mobilities of the Subunits of Coupling Factor 1 from Mitochondria" **Anal. Biochem.** 136, 362.
- 1 Feinstein, D.L. and Fisher, R.J. (1977) "On the DCCD Inhibition of the Escherichia Coli Adenosine Triphosphate Phosphohydrolase" **Biochem. J.** 167, 497.

Book Chapters:

1. Feinstein, D.L. and Heneka, M.T. (2017) "Potentiation of amyloid induced cortical inflammation by noradrenaline and noradrenergic depletion implications for Alzheimer s disease", in **"Noradrenergic Signaling and Astroglia"**, Editors: Zorec and Vardjan, Elsevier Press.
2. Feinstein, D.L. and Galea, E. (1998) "Competitive RT-PCR analysis of Brain Gene Expression" in Gene Quantitation, editor F. Ferre, Birkhauser, Boston, MA.
3. Ruggiero, D.A. and Feinstein, D.L. (1996) "The Autonomic System". In S. Mraovitch and R. Sercombe (Eds.) The Neurophysiological Basis of Cerebral Blood Flow Control: An Introduction., London: John Libby Eurotext
4. Feinstein, D.L., and Galea, E. (1993) "GFAP Isozyme Expression in PNS and CNS" in Biology and Pathology of Astrocyte-Neuron Interactions, Plenum Press (Federoff et al., Eds), New York, p. 431.

Selected Proceedings

1. Reis, D.J., Feinstein, D.L., Galea, E., and Golanov, E. (1997) "Cerebral Neurogenic Protection: Protection of Brain from Focal Ischemia by Cerebellar Stimulation" *Fundament. & Clin. Pharmacol.* 11 (1): S39-43.
2. Reis, D.J., Kobylarz, K., Feinstein, D.L., Galea, E., and Golanov, E. (1995) "Fastigial nucleus stimulation conditions neuroprotection and inhibits expression of inducible nitric oxide synthase gene after focal ischemia. *J. Cereb. Blood Flow Metab.* 15: S91.
3. Feinstein, D.L. (1997) Review of Second Annual Gene Quantification Meeting (California) January 6 - 7, Cambridge Healthtech Institute; Investigational Drugs Weekly Highlights, 4.
4. Feinstein, D.L., Galea, E., and Reis, D.J. (1995) "Astroglial Inducible Nitric Oxide Synthase Expression: Regulation in Vitro and In Vivo" 26th Meeting Amer. Soc. Neurochem. *J. Neurochem.* 64,
5. Feinstein, D.L., Galea, E., Xu, H. and Reis, D.J. (1995) "Heat shock protein 70 reduces expression of astroglial inducible nitric oxide synthase". Fourth International Meeting on the Biology of Nitric Oxide, Amelia Island, FL, Sept 17-21, page 333.
6. Feinstein, D.L., Galea, E., and Reis, D.J. (1994) "Suppression of Glial iNOS Expression by Tyrosine Kinase Inhibitors" *Annals NY Acad. Sci.* 738, 325-328.

Invited Talks (Bold indicates international)

- | | |
|-------|---|
| 03/19 | Dept Biology, University North Carolina "Treatment for LAAR poisoning". Host: J. Tie |
| 03/19 | Dept Pharmacy, Oakland University , Rochester, MI. "Treatments for EAE". Host: G. Chaudry |
| 01/19 | Dept Pharmacology, University Arizona, Tucson, AZ. "CRMP2 roles in EAE". Host: R. Khanna |
| 11/18 | Linus Pauling Institute, Corvallis, OR. "The emerging threat of Brodifacoum". Host: R van Breemen. |
| 09/18 | Dept Biology, University South Dakota, SD. "Regulation of EAE by CRMP2". Host: P Vitiello |
| 05/17 | Dept Anesthesiology, Kansas City Univ Med Ctr. "NA regulation of neurodegenerative diseases" |
| 11/16 | Dept Psychiatry, UIC, Chicago, IL. "Epigenetic actions of alcohol on microglial cells". Host: S Pandey |
| 08/16 | University of Bonn, Germany "LKE treatment of EAE". Host: M Heneka |
| 06/16 | Genzyme Translational Research Showcase, Boston "LKE potential for MS treatment" |
| 05/16 | Dept Pharmacology, Catholica University, Rome, Italy (invited but seminar cancelled). Host: C DelloRusso |

03/16 1st Annual CARE Alcohol Conference, UIC, Chicago, IL “Microglia and epigenetics of alcohol”
08/15 Dept Neurology, OHSU and Portland VAMC. Host: D. Bourdette; M Davey
05/15 Dept Neurology, U. Maryland and Baltimore VAMC. Host: C. Bever; B. Stern
12/10/14 Dept Cell Biology, UC Riverside. Host: S Tiwari-Woodruff
05/02/14 Dept Neuroscience, U. Cincinnati. Host: H. Titus-Mitchell
06/11/13 Dept Cell Biology, U. Toronto, **Canada**. Host: H. Mount
02/28/13 Dept Neurology, U. Bonn, **Germany**. Host: M Heneka
09/29/12 Dept Physiology, Wake Forest University, NC. Host: L. Porrino
01/19/12 Dept Cell Biology, Virginia Commonwealth University, VA. Host: G. DeVries
12/05/11 Dept Neurology, University Bonn, **Germany**. Host: M. Heneka
09/28/11 Biogen Idec, Cambridge, MA; Host: R. Scannevin
06/15/11 Wake Forest University Primate Center, Winston Salem, NC; Host: Jay Kaplan
05/03/11 Dept Pathology, University Madison, WI; Host: Albee Messing
06/10/10 Dept of Neuroscience, University of Kentucky; Host: Olivier Thiebault
06/08/09 Elan Pharmaceuticals, San Francisco, CA. Host: Kent Fitzgerald
02/15/09 Dept of Neurology, University of Bonn, **Germany**. Host: Michael Heneka
06/21/08 Dept Cell Biology and Anatomy, LSU, LO. Host: S. McClugage
05/28/08 Van Andel Institute, Grand Rapids, MI; Host: J. Callaghan
04/24/08 Cognitive Neurology & AD Center, NWU, Chicago, IL. Host: D. Monhardt
04/21/08 Graduate Program in Neuroscience, Thomas Jefferson Univ, Philadelphia, PA. Host: E. Van Bockstaele
01/14/08 Dept Neurology Grand Rounds, Rush Medical College. Chicago. Host: J. Goldman
12/12/07 Dept Pharmacology, Rush Medical College; Chicago. Host: K. Pahan
09/13/07 Dept Neuroscience & Anatomy, Univ. Toledo, OH.
04/24/07 Dept of Neurosciences Neurology, Case Western Reserver Univ; Cleveland, OH. Host: G Landreth
02/05/07 Dept of Anatomy & Cell Biology, UIC; Host: Orly Lazarov
09/01/06 MIND Institute, Sacramento, CA; Host: Bob Hendren
09/18/06 BiogenIdec, Boston, MA; Host: Jane Relton
11/09/04 Dept of Neurology, Univ of Arkansas Medical Science, Little Rock, AK; Host: S. Barger
06/17/04 Division of Research and Development, West Side VA, Chicago, IL; Host: S. Pandey
05/21/04 Dept of Neurosurgery, University of Wisconsin, Madison, WI. Host: A Vemuganti
04/05/04 Dept of Neurology, Medical University South Carolina, Charleston, SC. Host: I. Singh
02/12/04 Dept of Anatomy & Neurobiology, Thomas Jefferson University, Philadelphia, PA host: M. Rostami.
10/09/03 Dept of Anatomy & Neurobiology, Medical College Virginia, Richmond, VA; host: Babette Fuss.
09/19/03 Dept of Cellular and Structural Biology, UTHSCSA, TX Host: William Morgan
10/08/02 Dept of Physiology and Biophysic, University Illinois, Chicago, IL. Host: Sarah Appel
10/01/02 Dept of Neurobiology, Institute de Santi, Rome, **Italy**, host, L. Minghetti
05/07/02 Dept of Neurology, Wayne State Univ, Detroit, MI; host, Joyce Benjamins
04/24/02 Dept of Neurology, University Illinois, Chicago, IL; host, Dan Hier
12/18/01 Dept of Pathology, Albert Einstein College of Medicine, Bronx, NY; host: Peter Werner
12/17/01 Aventis Pharmaceuticals, Bridgewater, N.J. host: Jean Merrill
08/25/01 Neuroscience Program, University of Rio de Janeiro, **Brazil**; Host: Vivaldo Moura-Neto
06/06/01 IFR, Hopital Lariboisiere, INSERM U. 541, Paris, **France**; Host: Pierre Lacombe
06/04/01 Glaxo Smith Kline, Harlow, Essex, **England**; Host: Orest Hurko
04/19/01 Alzheimer’s Disease Center, Northwestern University, Chicago, IL
04/17/01 Dept of Rheumatology, University Illinois, Chicago, IL

Symposia and Colloquia (Bold indicates international)

10/16/19 Meeting Co-organizer and Speaker, 11th biAnnual Great Lakes Glial meeting, Traverse City, MI, USA
08/20/19 Speaker, “Natural supplement approach to treat neurodegenerative diseases”, 4th Annual Linus Pauling Research Symposium, Corvallis, OR, USA.
08/14/19 Speaker, “Career pathways in neurochemistry”, 49th Annual meeting of the American Society for Neurochemistry, **Montreal, Canada**.
03/23/19 Speaker, “Contribution of neuroinflammation to MS and AD”, Chicago Chapter of the Society for Neuroscience, Chicago, IL, USA
10/15/18 Instructor, 2nd Neuroinflammation School, **Conil de la Frontera, Spain**.
03/22/18 49th Annual American Society for Neurochemistry meeting. “Career paths and development”, CA, USA.
10/16/17 Meeting Co-organizer and session chair, 10th BiAnnual Great Lake Glial Meeting, Traverse City, MI
08/20/17 50th Bi-Annual meeting of the International Society for Neurochemistry, “Building a motivated research group around a good scientific problem”, **Paris, France**
06/12/17 Speaker, “Intralipid, a novel countermeasure against superwarfarins”, 11th annual meeting of the NIH Counteract Consortium, Denver, CO

- 06/15/16 Speaker, "Intralipid, a novel countermeasure against superwarfarins", 10th annual meeting of the NIH Counteract Consortium, Denver, CO
- 10/15/15 Meeting Co-organizer and session chair, 9th BiAnnual Great Lake Glial Meeting, Traverse City, MI
- 06/12/15 Speaker, "Intralipid, a novel countermeasure against superwarfarins", 9th annual meeting of the NIH Counteract Consortium, Denver, CO
- 06/17/14 Speaker, "Intralipid, a novel countermeasure against superwarfarins", 8th annual meeting of the NIH Counteract Consortium, Denver, CO
- 03/10/14 Chair and Speaker, 41st annual ASN Meeting "Novel roles for LKB1 in CNS", Long Beach, CA, TX.
- 10/06/13 Speaker, "Novel risk factors for MS", 6th bi-annual Great Lakes Glial Conference, Traverse City, MI
- 06/01/12 Speaker, "LC damage in AD: Causes and Cures" at 7th annual meeting Society for Brain Mapping and Translation, **Toronto, Canada**
- 05/02/12 Speaker "Noradrenergic dysfunction in AD and MS" given at 9th annual meeting on Neurodegeneration and Neurorepair, **Potsdam, Germany**
- 09/12/11 Chair and speaker in "Noradrenergic dysfunction in neurological diseases", given at the 10th biannual Euroglia meeting, **Prague, Czech.**
- 12/04/10 Speaker at the 2nd International Science Symposium on Myalgic Encephalomyelitis / Chronic Fatigue Syndrome, Bond University, **Queensland, Australia**
- 11/15/10 Speaker in NanoSymposium on Therapeutic Approaches for Alzheimer's Disease, 40th annual Society for Neuroscience meeting, San Diego, CA, USA
- 08/11/09 Chair and speaker in symposium "Therapeutic potential of PPAR agonists in neurological diseases and conditions", 22nd Biennial meeting of the International Society Neurochemistry, **Busan, South Korea.**
- 08/11/09 Speaker in colloquium, "Nitric Oxide Synthase type 2 and preconditioning", 22nd Biennial meeting of the International Society Neurochemistry, **Busan, South Korea.**
- 03/10/09 Chair and Speaker, 39th annual ASN Meeting "Novel and Contrasting roles for P2x receptors in Neurodegenerative Diseases", Charleston, SC
- 10/06/08 Speaker at the 9th International Conference on Alzheimer's Disease Drug Discovery "Anti-amyloidogenic effects of NA and PPARs", New York, NY.
- 03/01/08 Chair and Speaker, 38th annual ASN Meeting "Roles for Neurotransmitters in Neurodegenerative diseases", San Antonio, TX.
- 08/20/07 Chair and speaker, 21st biannual meeting International Society for Neurochemistry "Current Update of Nitric Oxide Synthase type 2", **Cancun, Mexico**
- 05/13/07 Speaker in symposium "Neuroprotection and Neurorepair: From Pharmacological to Stem Cell Therapies" held in recognition of new Neuroscience Institute at New Jersey Medical School, NJ; Host: Steve Levison and Barry Levin
- 05/01/07 Platform Presentation Results of a Phase I trial of Pioglitazone in RRMS patients", American Academy of Neurology 59th annual meeting, Boston, MA
- 03/30/07 Speaker in symposium "La maladie d'Alzheimer: Quoi de neuf apres un siecle de recherche?", Conference Fondation Andre-Delambre, Universite Laval, **Quebec.** Organizer : Jean-Pierre Julien
- 01/25/07 Chair and speaker, 40th Winter Brain Research Conference. Title "PPAR agonists in neurological conditions, a current update" Snowmass, CO, USA
- 03/14/06 Chair and speaker, 37th annual meeting , American Society for Neurochemistry "Novel Neuroprotective effects of the Stress Response", Portland, OR, USA
- 01/20/06 Chair and speaker, 39th Winter Brain Research Conference. Title "Modulation of Inflammatory Status in TgAPP mice", Copper Mountain, CO, USA
- 11/12/05 Speaker in mini-symposium at the 35th annual meeting, Society for Neuroscience: "Noradrenergic regulation of brain inflammation". Washington, DC, USA
- 03/20/05 Invited Speaker, 3rd International Symposium on "PPARs, efficacy and Safety". Title: PPARg agonists for treatment of MS: Initial Phase I results" **Monte Carlo, Monaco**
- 01/25/05 Speaker at the 38th Winter Brain Research Conference. Title: "PPAR agonists for treatment of demyelinating disease". Breckenridge, CO, USA
- 11/21/04 Invited Speaker, 4th International Symposium of GlaxoSmithKline Neurology and GI Research Series "Preclinical to Clinical Transition with AD therapeutics". **Prague, Czech Republic.**
- 09/29/04 Invited Speaker, 7th International Congress of Neuroimmunology, Title "Characterization of a novel complement receptor in astrocytes" **Venice, Italy.**
- 11/06/03 Chair and speaker in Symposium: "Novel Roles of Mitochondria in Neuroprotection", Society for Neuroscience 33rd Annual meeting, New Orleans, LA.
- 09/03/03 Chair and speaker in "Neurotransmitter Regulation of Glial Inflammatory Responses" session, VIth European meeting on Glial cell function in health and disease, Berlin, **Germany**
- 08/22/03 Invited speaker in "Actions of PPARg agonists on astroglial metabolism: Protective and anti-inflammatory effects", session, Sixth International Meeting on Brain Energy Metabolism, Satellite meeting of the 2003 ISN/ASP meeting, Beijing, **China** (postponed till March 2004)

03/19/03	Invited Speaker at the 2 nd International Symposium on “PPARs: from basic science to clinical applications”, Florence, Italy
09/26/02	Speaker at “Therapeutic Possibilities for CNS disease” conference, University of Perugia, sponsored by Glaxo Smith Kline, Perugia, Italy
06/22/02	Chair and speaker in “The emerging role of Peroxisome Proliferator Activated Receptors in Brain” session, American Society for Neurochemistry, 33 rd annual meeting, Palm Beach, FL.
05/27/00	Speaker on “Regulation of astroglial NOS expression by cAMP and the Heat Shock Response: In vitro and in vivo studies”, Fourth European meeting on Glial Cell Function, Barcelona, Spain .
03/28/00	Chair, “Contribution of Inflammatory Events to Pathogenesis of MS and Cerebral Ischemia: Similarities and Differences” session, American Society Neurochem. 32 nd meeting, Chicago, IL
09/25/99	Chair and speaker in “Astrocytes, Microglia, and the Immune System” session, Great Lakes Glia Meeting, Traverse City, MI.
08/17/99	Co-Chair and speaker in “The role of Nitric Oxide in Human NeuroPathology” session Satellite meeting of the 1999 ISN/ESN meeting in Berlin, at the University of Bonn, Germany .
01/06/97	Speaker, Cambridge Healthtech Insitute, 2 nd Annual Symposium on Gene Quantification, Coronado, CA. “Competitive RT-PCR Analysis of Brain Gene Expression During Inflammation and Disease”. Organizer: F. Ferre.

Mentoring

Postdoctoral fellows trained:

	Period	Current Position
Dr. Elena Galea, PhD	1991-1995	Professor, University Barcelona, Spain
Dr. Marius Stasiulek, MD	1998- 1998	Neurologist, University of Lodz, Poland
Dr. Michael T. Heneka, MD	1999-2000	Professor, University Bonn, Germany
Dr. Vitalily Gavriluk, MD, PhD	1998-2003	Assistant Research Professor, UIC, Chicago, USA
Dr. Cinzia Della Russo, MD, PhD	2002-2005	Research Professor, Catholic University, Rome, Italy
Dr. Olga Kalinin, PhD	2004-2005	Research Associate, Univ Chicago, USA
Dr. Jose Munoz Madrigal, PhD	2004-2006	Associate Professor, Univ of Madrid, Spain
Dr. Sergey Kalinin, PhD	2004-2006	Assistant Research Professor, UIC, Chicago, USA
Dr. Alessandra Spagnolo, PhD	2004-2006	Research Associate, Complutense, Madrid, Spain
Dr. Claudia Kaiser, MD	2004-2007	Staff Neurologist, Univ Bochum, Germany
Dr Natalia Marangoni	2013-2017	Teva Pharmaceuticals, Chicago, IL

Graduate Students

	Primary Dept	Period	Thesis Topic
Dinesh Shuklah	Bioengineering	2004-2007	DTI and fMRI Analysis of RRMS
Elizabeth Menig	Neuroscience	2006-2008	Noradrenergic regulation of NOS2
Vittoria Simonini	Neuroscience	2006-2010	Studies on Oligodendrocyte maturation
Lucia Lisi	Neuroscience	2008-2012	Studies on astrocyte inflammation and EAE
David Braun	Neuroscience	2011-2016	Studies on neuronal maturation
Elizabeth Boots	Psychology	2018-present	Inflammation and AD

Medical Students and Residents Trained in Research:

Jenny Kwak	1999-2000	Dept Anesthesiology, UIC
Per Theobald	2000-2001	Dept Anesthesiology, UIC
Pilar Mercado	2002-2003	Dept Anesthesiology, UIC
Patrick Ziemann-Gimel	2002-2003	Dept Anesthesiology, UIC
Mark Jacobs	2000-2001	Dept Anesthesiology, UIC
Alex Ksendzovsky	2008	Mount Sinai School of Medicine, Chicago
Ryan Zengou	2008	Dept of Neurosurgery, Rush Medical College, Chicago
Gunar Subieta	2008	Dept of Anesthesiology, UIC
Michele Apple	2008	UIC Medical College
Ife Ebebuwa	2010-2011	UIC Medical College
Pilar Mercado	2010-2011	Intern, Dept Anesthesiology, UIC
Michael Fettiplace	2011	UIC Medical College
Ali Ghods	2012-2014	Rush University Medical University
Daniel Roshan	2015-2016	Resident, Dept Anesthesiology, UIC
Kingas Lis	2015-2017	Dept Pharmacology, UIC
David Gavin	2015-present	CDA Mentor, Dept Psychiatry, UIC
Benjarat Changyaleket	2016-present	Attending, Dept Anesthesiology, UIC

PhD Thesis Committees

July 2003	Olivera Pluzarev	Dept Cell Biology and Anatomy, UIC
-----------	------------------	------------------------------------

April 2004	Steven Smith	School of Pharmacy, University of Queensland, Australia
Dec 2004	Xin Li	Dept of Cell Biology and Anatomy , UIC
March 2005	Eunjung Jeon	Dept of Biopharmaceutical Sciences, UIC
March 2007	Yimei You	Dept Cell Biology and Anatomy, UIC
April 2007	Samer Abdul-Hay	Dept of Medicinal Chemistry & Pharmacognosy, UIC
June 2008	Chang You	Dept of Psychiatry, UIC
April 2008	Weiguo Li	Dept of Bioengineering, UIC
July 2008	Ashwini Pai	Dept of Biopharmaceutical Sciences, UIC
Oct 2008	Adam White	Dept of Cell Biology and Anatomy, UIC
Oct 2008	Ben Smith	Dept of Cell Biology and Anatomy, UIC
Nov 2008	Michael Debars	Dept of Cell Biology and Anatomy, UIC
May 2010	Benjamin Smith	Dept of Cell Biology and Anatomy, UIC
June 2010	Ming Liu	Dept of Bioengineering, UIC
June 2010	Hong Ling	Dept of Cell Biology and Anatomy, UIC
<u>2011 to 2015</u>	Evelyn Nwabuisi	Dept of Cell Biology and Anatomy, UIC
	Chang You	Dept of Psychiatry, UIC
	Kasia Pituch	Dept of Cell Biology and Anatomy, UIC
	Lucia Lisi	Dept of Cell Biology, University Catholica, Rome, Italy
	Marta Santo	Dept of Cell Biology and Anatomy, UIC
	Kasia Pusch	Dept of Cell Biology and Anatomy, UIC
	Felicia Martes	Dept of Cell Biology and Anatomy, UIC
	Beverly Francis	Dept of Cell Biology, U. Toronto, Canada
<u>2016</u>	Evan Kyzar	Dept of Psychiatry, UIC
	Felecia Marottoli	Dept of Cell Biology and Anatomy, UIC
	Nancy Long Bertolotti	Dept of Cell Biology and Anatomy, UIC
	Zane Hauck	Dept of Medicinal Chemistry & Pharmacognosy, UIC
	Jennifer Ross	Dept of Pharmacology, Drexel University, PA
<u>2017</u>	Elijah Loda	Dept Neuroscience, Rush University, Chicago

Recent Undergraduate and High School Student Mentoring

2018-2018	Karolina Ryszka	Walter Payton College Prep School, Chicago
2017-2018	Monica Hernandez	UIC undergraduate
2017-2018	Sara Allison	UIC undergraduate
2017-2018	Farheen Fatima	UIC undergraduate
2016-2018	Harashita Degala	Illinois Math and Science Academy
2015-2016	Annie Situ	UIC undergraduate
2014-2016	Charamaine Ong	Illinois Math and Science Academy
2013-2015	Hirali Shah	UIC undergraduate
2013	Vandana Karan	Illinois Math and Science Academy
2012	Akshay Verma	Illinois Math and Science Academy
2010	Faraz Khan	UIC undergraduate

Training grants

2017	Member T32 for Alzheimer's Training Program, UIC
2016	Member T32 for Medical Scientist Training Program, UIC

Support (Bold for NIH, DOD, VA)

ACTIVE

NIH U01NS083457 (Feinstein)	9/1/13-8/31/18	3.0 calendar
	<i>In NCE till 8/31/19</i>	
Intralipid, a novel counterdefense against chemical threats	\$453,000 annual direct	
Goals are to develop use of intra osseous delivered Intralipid to reduce toxicity and neurological damage due to superwarfarins in civilian and military populations		

Dept Veterans Affairs, Merit (Feinstein)	01/1/16-12/31/19	3.0 calendar
Identification and characterization of a novel risk factor for MS	\$150,000 annual direct	
Goal is to characterize the LKB1 kinase in EAE and MS patients, including full genomic sequencing, RNA profiling, and generation of new mouse models targeting LKB1 expression.		

NMSS IIG (Feinstein) 10/01/15- 9/30/182.0 calendar
In NCE till 9/30/19
Neuroprotective Effects of the CRMP2 Activator Lanthionine Ketmine Ester in EAE \$200,000 annual direct
Goal is to test effects of lanthionine ketimine ester on axonal repair in a chronic EAE model of MS

Dept of Veteran Affairs (Feinstein) 10/01/14-9/30/19 3.0 calendar
BLR&D Research Career Scientist GS15/02 \$151,000 annual direct
This RCS provides salary support to engender research in neurodegenerative diseases and conditions

NIH R21 (Feinstein) 9/1/18 -8/31/20
Approved by council, pending funding for FY19
Cholestyramine to treat superwarfarin poisoning \$275,000 total direct requested
Goal is to optimize cholestyramine treatment to reduce mortality due to superwarfarins.

NIH 1R01DK117102-01A1 (PI: Brodsky, Feinstein, Consultant) 02/01/19-11/30/23
Anticoagulant related nephropathy
Goals are to examine nephrotoxic effects of warfarin and anti coagulants

PENDING

NIH R01 (Feinstein) 12/1/19-11/30/24
Roles for CRMP2 in EAE and oligodendrocyte maturation \$1,250,000 direct requested
Goals are to characterize function and modulation of CRMP2 during EAE

NMSS IIG (Feinstein) 12/1/19-11/30/24
Roles for CRMP2 in EAE and oligodendrocyte maturation \$650,000 direct requested
Goals are to characterize function and modulation of CRMP2 during EAE

NIH R01 (Roth, PI; Feinstein, CoInv) 12/1/19-11/30/24
Extracellular vesicles and retinal ischemia \$1,400,000 direct requested
Goals are to test extracellular vesicles for protection against retinal damage

NMSS IIG (Chaudry, PI; Feinstein, CoConsultant) 12/1/19-11/30/24
Effects of MSC transplantation on development of EAE

NIH R21 (Feinstein) 9/1/20-8/31/25
Identification of novel compounds to enhance superwarfarin clearance \$275,000 direct requested
Goals are to optimize CSA to reduce recirculation and increase clearance of BDF from poisoned animals.

In Preparation

NIH U01 (Feinstein) 9/1/20-8/31/25 (submission 9-1-19)
Intralipid optimization for BDF poisoning \$500,000 annual direct requested
Goals are to optimize lead compound Intralipid to reduce toxicity and neuropathology due to superwarfarins

Dept Veterans Affairs, Merit (Feinstein) 12/1/19-11/30/23 (submission 7-1-19)
Effects of alcohol on amyloid clearance \$150,000 annual direct requested
Goal is to determine how alcohol influences microglial function in regulation of amyloid burden in mice and humans

Previous (PI unless noted)

NIH/NIAAA P50 (PI pilot project #2; *Pandey, JBVAMC, PI*) 4/1/15-3/30/17
Epigenetic control of alcohol induced glial cell activation \$50,000 annual direct

NIH 3U01NS083457-02S1 9/01/2014-08/31/2015
Intralipid: A novel frontline countermeasure for brodifacoum poisoning \$100,000 direct

Dept Veteran Affairs SHEeP grant (CoPI) 2014
Funds awarded to JBVAMC for Shimadzu LC-8050 HPLC/MS/MS \$500,000

Dept of Veteran Affairs 9/01/09-8/31/14
BLR&D Research Career Scientist GS14/04 \$116,000 annual direct

RG 4483A10/1 National MS Society Locus Coeruleus damage in EAE and MS	4/01/11 – 3/31/14 \$150,000 annual direct
IL 0002 Illinois Lottery MS Pilot Grant Targeting CRMP2 from treatment of MS	10/01/12- 9/30/13 \$100,000 annual direct
Dept of Veteran Affairs Merit Grant (PI) “Noradrenergic regulation of neuronal activation”	04/01/08 – 03/31/12 \$914,000 total direct
Department of Defense (CoPI; E. Bongarzone CoPI) Mobilization of neural progenitor cells in MS	11/01/09 – 11/1/12 \$23,000 total direct year (to DF)
Metabolic Solutions Discovery (PI) Studies of PPARg sparing TZDs in TgAPP mice	\$15,000 unrestricted gift
American Alzheimer’s Association “Noradrenergic regulation of amyloid processing”	08/1/08-07/31/11 \$220,000 total direct
NINDS/NIH R13 conference grant 42nd Annual ASN meeting	3/19/11 – 3/23/11 \$25,000 total
NINDS/NIH 1 RO1 NS055337 (PI) “Treatment of demyelinating disease with HSP90 inhibitors” \$810,000 total direct	01/01/07-12/31/10
American Alzheimer’s Association (Mentor) “Characterization of LC damage in TgAPP mice”	09/1/08 – 08/31/10 \$90,000 total direct
Institute for Studies of Aging (ISOA): PI “Regulation of Amyloid burden by novel TZDs”	07/01/09-07/01/10 \$100,000 total direct
Partners for Cures (PI) Effects of Raisng Central Noradrenaline in mouse model of MS	1-1-09 to 1-1-10 \$17,500 total direct
Biogen (PI) Metabolic effects of BG12 in neurons and glia	\$15,000 total direct
National MS Society PP: PI “Regulation of Noggin in Astrocytes”	09/01/07-08/31/08 \$40,000 direct /1 yr
NINDS/NIH R13 conference grant 41 st Annual ASN meeting	\$25,000 total
Institute for Studies of Aging (ISOA): PI “Regulation of Amyloid burden by Noradrenaline and PPARd Agonists	07/01/07-07/01/08 \$90,000 direct / 1yrs
National MS Society RG 3545-A-7 “Therapeutic Potential of PPARdelta Agonists”	10/01/04-09/30/07 \$334,000 direct
NINDS/NIH 1 RO1 NS44945-01 “Role of IkappaB in control of Glial Inflammation”	12/01/02-11/31/06
NINDS/NIH 1 RO1 NS44945-S01 “Noradrenergic regulation of mitochondrial function” Career re-entry award for J. Palmer; supplement to NS44945	12/01/04-11/31/06
National Mutliple Sclerosis Society (Mentor to Dr. Dello Russo) “Noradrenergic Regulation of Microglial Nitric Oxide Synthase”	08/01/03-07/31/06
Dept of Veteran Affairs Merit Grant: PI	04/01/02-03/30/06

“Regulation of Brain Inflammation by Noradrenaline and Thiazolidinediones”

NIH, R21: (Co-Investigator; Weinberg PI) “TZD Treatment of Cocaine Toxicity”	04/01/04-03/31/06
American Alzheimer’s Association “Regulation of Neuronal Nitric Oxide Synthase Expression”	10/01/02-11/31/05
National Multiple Sclerosis Society Competitive Pilot Project PP0800 “Suppression of EAE by PPAR γ agonists”	05/01/01-04/30/02
NINDS/NIH 1 RO1 NS31556-01A3 “Glial Nitric Oxide Synthase: Regulation of Expression”	04/01/97-3/30/00
NINDS/ NIH 5PO1 HL018974-259001 (Reis, PI) “Mechansims of Central Neurogenic Neuroprotection” PI: Neurochemistry / Molecular Biology Core	07/01/99-06/30/03
National Multiple Sclerosis Society RG 2578-B-5 “Regulation of Nitric Oxide Synthase in Glial Cells”	10/01/96-03/31/00
National Multiple Sclerosis Society Pilot Project PP0628 “Experimental Allergic Encephalomyelitis in HSP70 Transgenic Mice”	09/01/99-08/30/00
National Multiple Sclerosis Society RG 2578-3 “Regulation of Nitric Oxide Synthase in Glial Cells”	10/01/93-09/30/96
National Multiple Sclerosis Society RG 24657 A2/1 “GFAP Expression in Development and Disease”	10/01/92-09/30/95

Collaborative Studies with Pharmaceutical Companies

2013-2016	Boehringer Ingelheim, Germany Comparison of Pradaxa to Warfarin on CNS pathology
2013-2015	Sanofi Aventis, Boston, MS Screening vincamine derivatives for neuronal maturation effects
2008-2014	Biogen Idec, Cambridge, MA Metabolic effets of BG0012 (Dimethyl Fumarate) in neural cells.
2006-2012	Metabolic Solutions Development, Kalamazoo, Michigan Testing of novel TZDs in animal models (AD and MS)
2009-2011	EJ Lilly, Indianapolis, IN Effects of NA reuptake inhibitors in neurodegenerative diseases
2008-2011	Chelsea Therapeutics, Durham, NC Testing of novel NA precursors in animal models of AD and MS
2001-2009	Glaxo Smith Kline; Harlow, England Effect of PPAR agonists, mAbs, and P2X7R blockers in EAE and MS
2002-2008	Takeda Pharmaceuticals North America, Lincolnshire, IL Use of Pioglitazone in EAE and MS
2004-2008	Pierre Farbre, Castres, France Use of $\alpha 2$ antagonists for brain inflammation
2004-2006	Conforma Inc; San Diego, CA Testing HSP90 inhibitors in EAE
2004-2005	Pfizer, St .Louis, MO; Effect of PPAR agonists on mitochondrial functions

Pharmaceutical Grants Completed

Boehringer Ingelheim	9/1/13 – 8/1/15
Neurological effects of warfarin versus pradaxa	\$100,000 annual direct
Goal was to compare neuroinflammation in mice after treatment with warfarin versus pradaxa	

Biogen Idec Genetic analysis of a novel MS family Goal was to carry out initial genetic analysis for novel risk factors in a unique population of MS patients	3/1/13 – 8/30/14 \$50,000 annual direct
Glaxo Smith Kline, Harlow, England, PI Development of EAE in P2X7 null mice	09/06-09/07 \$110,000 direct /1.5 yrs
Takeda Pharmaceuticals North America: PI “Pilot Trial of Actos in Multiple Sclerosis”	01/01/04-01/01/07 \$225,000 direct
Glaxo Smith Kline, Harlow, England, PI Effects of humanized mAbs directed against MAG and NOGO in EAE	09/05-03/07 \$25,000
Glaxo Smith Kline, Harlow, England, PI Effects of PPAR Agonists on Demyelinating Disease: PreClinical Analyses	01/01/04-06/01/05 \$125,000
Glaxo Smith Kline, Harlow, England “Use of PPAR agonists for neurodegenerative diseases”	02/01/02-01/31/03 \$100,000
Conforma Therapeutic, San Diego, CA: PI “Examination of HSP90 inhibitors in glial inflammation and EAE”	2004-2005 \$10,000
Pierre Farbes, BOULOGNE CEDEX, FRANCE, “Noradrenergic modulation of beta-amyloid-induced cortical inflammation: effects of alpha-2 adrenoceptor antagonists in vivo”	01/01/04-07/01/04 \$10,000
Takeda Pharmaceuticals North America, Chicago, IL, PI “Examination of Pioglitazone for treatment of demyelinating disease”	01/01/03-06/30/04 \$125,000
Takeda Pharmaceuticals North America, Chicago, IL “Examination of Pioglitazone for treatment of demyelinating disease”	09/01/01-08/31/02 \$100,000

References

Guy Weinberg, MD

guyw@uic.edu

Professor, Jesse Brown VA Medical Center
Dept of Anesthesiology, University of Illinois
1740 W Taylor St,
Chicago, IL 60612

Israel Rubinstein, MD

rudi.rubinstein@gmail.com

Associate Chief of Staff
Jesse Brown VA Medical Center
Chicago, IL, 60612
Phone: 312 567 6343

Monica Carson, PhD

monica.carson@ucr.edu

Professor and Chair BioMedical Sciences
University of California Riverside, School of Medicine
Phone: (951) 827-6089

Etty (Tika) Benveniste, Ph.D.

tika@uab.edu

Professor and Chair
Department of Cell Biology
Associate Director, Basic Science Research
Comprehensive Cancer Center
Birmingham, AL 35294-0005
Phone: (205) 934-7667

George H. De Vries Ph.D.

George.Devries@va.gov

Career Research Health Scientist
McGuire VA Medical Center
Richmond, VA